Cubist Systematic Strategies LLC Invests $218,000 in AC Immune SA (NASDAQ:ACIU)

Cubist Systematic Strategies LLC acquired a new position in AC Immune SA (NASDAQ:ACIU) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 54,610 shares of the company’s stock, valued at approximately $218,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Lazard Asset Management LLC purchased a new stake in AC Immune during the first quarter worth $30,000. BNP Paribas Financial Markets boosted its holdings in AC Immune by 315.6% during the first quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after buying an additional 8,423 shares in the last quarter. Silverberg Bernstein Capital Management LLC purchased a new stake in AC Immune during the second quarter worth $40,000. China Universal Asset Management Co. Ltd. boosted its holdings in AC Immune by 96.5% during the first quarter. China Universal Asset Management Co. Ltd. now owns 19,008 shares of the company’s stock worth $56,000 after buying an additional 9,334 shares in the last quarter. Finally, Vanguard Capital Wealth Advisors purchased a new stake in AC Immune during the second quarter worth $56,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. StockNews.com downgraded shares of AC Immune from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of AC Immune in a report on Wednesday, September 18th.

AC Immune Stock Down 3.9 %

Shares of NASDAQ ACIU opened at $3.19 on Tuesday. The firm has a 50-day simple moving average of $3.36 and a 200-day simple moving average of $3.40. The stock has a market capitalization of $315.49 million, a price-to-earnings ratio of -4.62 and a beta of 1.25. AC Immune SA has a 52 week low of $2.20 and a 52 week high of $5.14.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Tuesday, August 6th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $91.60 million. As a group, equities research analysts expect that AC Immune SA will post -0.89 EPS for the current year.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.